Characterization of the significant decline in humoral immune response six months post‐SARS‐CoV‐2 mRNA vaccination: a systematic review
KI Notarte, I Guerrero‐Arguero… - Journal of medical …, 2022 - Wiley Online Library
Accumulating evidence shows a progressive decline in the efficacy of coronavirus disease
2019 (COVID‐19)(severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]) …
2019 (COVID‐19)(severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]) …
The effect of smoking on humoral response to COVID-19 vaccines: a systematic review of epidemiological studies
While the role of active smoking on response to vaccines is yet to be fully understood, some
real-world studies have outlined a possible link between smoking and humoral response to …
real-world studies have outlined a possible link between smoking and humoral response to …
Persistence in risk and effect of COVID-19 vaccination on long-term health consequences after SARS-CoV-2 infection
The persisting risk of long-term health consequences of SARS-CoV-2 infection and the
protection against such risk conferred by COVID-19 vaccination remains unclear. Here we …
protection against such risk conferred by COVID-19 vaccination remains unclear. Here we …
Does smoking have an impact on the immunological response to COVID-19 vaccines? Evidence from the VASCO study and need for further studies
P Ferrara, D Ponticelli, F Agüero, G Caci, A Vitale… - Public Health, 2022 - Elsevier
Objectives The aim of this study was to investigate the possible impact of smoking on the
humoral response to the BNT162b2 mRNA COVID-19 vaccine (also known as the BioNTech …
humoral response to the BNT162b2 mRNA COVID-19 vaccine (also known as the BioNTech …
Patients with liver cirrhosis show high immunogenicity upon COVID-19 vaccination but develop premature deterioration of antibody titers
K Willuweit, A Frey, M Passenberg, J Korth, N Saka… - Vaccines, 2022 - mdpi.com
SARS-CoV-2 infection is known to lead to severe morbidity and mortality in patients with
liver cirrhosis. For this reason, vaccination of these patients against COVID-19 is widely …
liver cirrhosis. For this reason, vaccination of these patients against COVID-19 is widely …
An immunological review of SARS-CoV-2 infection and vaccine serology: innate and adaptive responses to mRNA, adenovirus, inactivated and protein subunit …
The coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, which is defined by its positive …
respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, which is defined by its positive …
Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals
Abstract Background Two mRNA vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273,
obtained the Emergency Use Listing by WHO for preventing COVID-19. However, little is …
obtained the Emergency Use Listing by WHO for preventing COVID-19. However, little is …
Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case–control study
Background In view of limited evidence that specifically addresses vaccine effectiveness
(VE) in the older population, this study aims to evaluate the real-world effectiveness of …
(VE) in the older population, this study aims to evaluate the real-world effectiveness of …
Homologous and heterologous anti-COVID-19 vaccination does not induce new-onset formation of autoantibodies typically accompanying lupus erythematodes …
The COVID-19 pandemics has caused the death of almost six million people worldwide. In
order to establish collective immunity, the first vaccines that were approved in Germany were …
order to establish collective immunity, the first vaccines that were approved in Germany were …
Time-varying effect of hybrid immunity on the risk of breakthrough infection after booster dose of mRNA COVID-19 vaccine: the MOSAICO study
P Ferrara, D Ponticelli, R Magliuolo, M Borrelli… - Vaccines, 2022 - mdpi.com
This longitudinal observational study investigated the risk of breakthrough SARS-CoV-2
infection up to 6 months after a booster dose of an mRNA COVID-19 vaccine in infection …
infection up to 6 months after a booster dose of an mRNA COVID-19 vaccine in infection …